The initial facilities in the South Warwickshire region adopting the technology include the Stratford Upon Avon and Warwick hospitals, with a wider rollout planned as vaccine distribution progresses.
The various COVID-19 vaccines, including the one developed by Pfizer and now approved for use in the UK, require exact degrees of cold storage at all times in order to maintain their efficacy.
While centralized distribution centers and transportation units can store the vaccine at the recommended -70°C±10°C for up to 10 days unopened, they must also be stored at hospitals and other administering centers for five days at refrigerated 2-8°C conditions.
Everyware provides asset tracking and monitoring software that can be configured to monitor a number of variables, including temperature, on a 24/7 basis, from anywhere.
By leveraging Everyware's asset monitoring solution at the 'last mile', hospitals and healthcare facilities can ensure that vaccines are being maintained at the proper temperature throughout the entire time in their custody, before they are administered to patients.
In addition, Everyware enables healthcare facilities to share information with other parts of the vaccine delivery chain including pharmaceutical providers, centralized storage facilities, and transportation companies, to respond and adjust to any issues as they arise.
Everyware's offering already provides this service for a number of other healthcare and pharmaceutical assets, including chemotherapy and other drugs, and blood and plasma, all of which have their own unique storage requirements.
Hedera is a decentralized public platform on which developers can build secure, fair, fast, trusted applications.
The platform is governed by a council of the world's leading organizations including Avery Dennison, Boeing, Deutsche Telekom, Dentons, DLA Piper, FIS (WorldPay), Google, IBM, LG Electronics, Magalu, Nomura, Swirlds, Tata Communications, University College London, Wipro, and Zain Group.
Pfizer reports positive Phase 3 data for ABRYSVO in adults at risk for RSV disease
Clover Bio announces SCB-1019 vaccine candidate Phase I trial data in initial young adult cohort
Sanofi launches Verorab for rabies prophylaxis in UK
BioVaxys expands patent portfolio for DPX delivery platform and advances DPX SurMAGE
YS Biopharma repays USD40m loan facility
Kintara Therapeutics and TuHURA Biosciences to merge
VGXI names new chief accounting officer
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Valneva launches Phase 1 trial for next-generation Zika vaccine
Circio Holding ASA confirms licensing deal with IOVaxis Therapeutics in China and Singapore
Everest Medicines names new chief medical officer and chief product officer
Pfizer's PREVENAR 20 gains European Commission approval for paediatric pneumococcal vaccine